Benitec Biopharma Inc. (BNTC) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
3940 TRUST WAY HAYWARD, CA 94545 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 MRQ | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 50,866 | 2,477 | 4,062 | 19,769 | 9,801 | |||
| Cash and cash equivalent | 50,866 | 2,477 | 4,062 | 19,769 | 9,801 | |||
| Restricted cash and investments | 63 | 13 | 14 | |||||
| Receivables | 59 | |||||||
| Other current assets | 949 | |||||||
| Other undisclosed current assets | 745 | 1,239 | 744 | 839 | ||||
| Total current assets: | 51,674 | 3,729 | 4,820 | 20,608 | 10,809 | |||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 270 | 526 | 771 | 202 | 395 | |||
| Property, plant and equipment | 179 | 87 | 222 | 375 | 374 | |||
| Other noncurrent assets | 62 | 97 | 135 | 185 | ||||
| Other undisclosed noncurrent assets | 25 | 25 | 25 | 9 | 9 | |||
| Total noncurrent assets: | 536 | 735 | 1,153 | 771 | 778 | |||
| TOTAL ASSETS: | 52,210 | 4,464 | 5,973 | 21,379 | 11,587 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 2,061 | 1,756 | 1,424 | 737 | 890 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 400 | 276 | 203 | ||
| Accounts payable | 1,351 | 1,140 | 422 | 274 | 282 | |||
| Accrued liabilities | 710 | 616 | 602 | 187 | 405 | |||
| Other undisclosed current liabilities | 2,863 | 2,222 | 1,108 | 632 | 246 | |||
| Total current liabilities: | 4,924 | 3,978 | 2,532 | 1,369 | 1,136 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation: | 559 | 213 | ||||||
| Liabilities, other than long-term debt | 284 | |||||||
| Operating lease, liability | 284 | 559 | 213 | |||||
| Other undisclosed noncurrent liabilities | 38 | (559) | (213) | |||||
| Total noncurrent liabilities: | 38 | 284 | 559 | 213 | ||||
| Total liabilities: | 4,962 | 4,262 | 3,091 | 1,369 | 1,349 | |||
| Equity | ||||||||
| Equity, attributable to parent | 47,248 | 202 | 2,882 | 20,010 | 10,238 | |||
| Common stock | 1 | 1 | 1 | 1 | ||||
| Additional paid in capital | 238,398 | 168,921 | 152,453 | 151,583 | 128,826 | |||
| Accumulated other comprehensive loss | (892) | (830) | (1,245) | (1,455) | (1,953) | |||
| Accumulated deficit | (190,259) | (167,889) | (148,327) | (130,119) | (116,636) | |||
| Total equity: | 47,248 | 202 | 2,882 | 20,010 | 10,238 | |||
| TOTAL LIABILITIES AND EQUITY: | 52,210 | 4,464 | 5,973 | 21,379 | 11,587 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 75 | 73 | 59 | 102 | |||
| Gross profit: | 75 | 73 | 59 | 102 | |||
| Operating expenses | (22,490) | (19,156) | (17,927) | (13,655) | (8,383) | ||
| Operating loss: | (22,490) | (19,081) | (17,854) | (13,596) | (8,281) | ||
| Nonoperating income (expense) | 739 | (481) | (354) | (286) | 7 | ||
| Gain (loss), foreign currency transaction, before tax | 40 | (415) | (232) | (333) | (88) | ||
| Other nonoperating income (expense) | (204) | (30) | (79) | 37 | 34 | ||
| Interest and debt expense | |||||||
| Loss from continuing operations: | (21,751) | (19,562) | (18,208) | (13,882) | (8,274) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (18,208) | (13,882) | (8,274) | |
| Net loss: | (21,751) | (19,562) | (18,208) | (13,882) | (8,274) | ||
| Other undisclosed net loss attributable to parent | |||||||
| Net loss attributable to parent: | (21,751) | (19,562) | (18,208) | (13,882) | (8,274) | ||
| Preferred stock dividends and other adjustments | (619) | ||||||
| Other undisclosed net loss available to common stockholders, basic | (0) | ||||||
| Net loss available to common stockholders, diluted: | (22,370) | (19,562) | (18,208) | (13,882) | (8,274) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (21,751) | (19,562) | (18,208) | (13,882) | (8,274) | ||
| Comprehensive loss: | (21,751) | (19,562) | (18,208) | (13,882) | (8,274) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (62) | 415 | 210 | 498 | (89) | ||
| Comprehensive loss, net of tax, attributable to parent: | (21,813) | (19,147) | (17,998) | (13,384) | (8,363) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.